¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"common acute lymphoblastic leukemia antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • antigen, transplantation
    À̽ÄÇ׿ø
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,carcinoembryonic
    ¾ÏÁ¾¹è¾Æ¼º(äßðþÛÏä´àõ)
  • antigen,fetal
    žƼº(÷Ãä®àõ)
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • antigen,heyman
    ÇìÀ̸¸
  • antigen,histocompatibility
    Á¶Á÷ÀûÇÕ¼º(ðÚòÄîêùêàõ)
  • antigen,hla- d
    HLA-D
  • antigen,oncofetal
    Á¾¾çžƼº(ðþåË÷Ãä®àõ)
  • antigen,sequestered
    °Ý¸®(̰×î)
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • antigen-antibody complex
    Ç׿ø-Ç×üº¹ÇÕü
  • antigen-antibody complex, soluble
    ¼ö¿ë¼º Ç׿ø-Ç×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿ø-Ç×ü»óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • monocytic leukemia
    ´Ü(ÇÙ)±¸¼º ¹éÇ÷º´(Ó¤ú·Ï¹àõÛÜúìÜ»).
  • monocytic leukemia
    ´Ü(ÇÙ)±¸¼º ¹éÇ÷º´(ËÀÌ´Ë´ËÛËÑÌ´ËÓ).
  • monomyelogenous leukemia
    ´Ü±¸°ñ¼ö¼º ¹éÇ÷º´(ӤϹÍéâÐàõÛÜúìÜ»).
  • monomyelogenous leukemia
    ´Ü±¸°ñ¼ö¼º ¹éÇ÷º´(ӤϹÍéâÐàõÛÜúìÜ»)
  • monomyelogenous leukemia
    ´Ü±¸°ñ¼ö¼º ¹éÇ÷º´(ËÀË´Ë­ËàËÛËÑÌ´ËÓ).
  • mouse leukemia virus
    ¸¶¿ì½º ¹éÇ÷º´¹ÙÀÌ·¯½º
  • mouse leukemia virus
    ¸¶¿ì½º ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • murine leukemia virus
    ¸¶¿ì½º ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • myeloblastic leukemia
    °ñ¼ö¾Æ±¸ ¹éÇ÷º´
  • myeloblastic leukemia
    °ñ¼ö¸ð±¸<¼¼Æ÷>¼º ¹éÇ÷º´(¡­Ï¹<á¬øà>àõÛÜúìÜ»)
  • myeloblastic leukemia
    °ñ¼ö¸ð±¸<¼¼Æ÷>¼º ¹éÇ÷º´(?Ë´<ËṴ̂>ËÛËÑÌ´ËÓ).
  • myelogenous leukemia
    °ñ¼ö¼º ¹éÇ÷º´(Ë­ËàËÛËÑÌ´ËÓ).
  • myelogenous leukemia
    °ñ¼ö¼º ¹éÇ÷º´(ÍéâÐàõÛÜúìÜ»)
  • myeloid leukemia
    °ñ¼ö¼º ¹éÇ÷º´(?ËÛËÑÌ´ËÓ).
  • myeloid leukemia
    °ñ¼ö¼º ¹éÇ÷º´(¡­àõÛÜúìÜ»)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
TL temporal lobe; terminal limen; thermolabile; thermoluminescence; threat to life; thymus-leukemia [an...
TLA thymus leukemia antigen; tissue lactase activity; tongue-to-lip adhesion; translaryngeal aspiration;...
AMI Acute Myocardial Infarction
  - Complications(Cx)
    1. Early ...
AC abdominal circumference; abdominal compression; absorption coefficient; abuse case; acetate; acetylc...
ACE acetonitrile; acetylcholine esterase; acute cerebral encephalopathy; acute coronary event; adrenocor...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
BCL1 B cell leukemia
CLL Chronic Lymphoid Leukemia
CML Chronic myelocytic leukemia
CMMol Chronic myelomonocytic leukemia
FLC Friend Leukemia Cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute pseudomembranous candidosis
    ±Þ¼º À§¸·¼º ĵµð´ÙÁõ
  • acute psychologic distress
    ±Þ¼ºÀÇ Á¤½ÅÀû °íÅë
  • acute pulpitis
    ±Þ¼º Ä¡¼ö¿°
    Ä¡¼öÀÇ ±Þ¼º ¿°ÁõÀÌ´Ù. Ä¡¾Æ¿ì½ÄÁõÀ¸·Î ÀÕµû¶ó ¹ß»ýÇÏ´Â °Í°ú ¿Ü»óÀÌ ¿øÀÎÀÎ °ÍÀ¸·Î ±¸ºÐÇÑ´Ù. ¸ðµÎ ½ÉÇÑ ÅëÁõÀÌ ÁÖµÈ Áõ»óÀÌ´Ù. ÈÄÀÚ¿¡ À־´Â ÁøÅëÁ¦ Åõ¿©·Î Áõ»óÀÌ °¡¶ó¾É´Â °ÍÀÌ ¸¹Àºµ¥, ÀüÀÚÀÇ °æ¿ì ÁøÅëÁ¦·Î È¿°ú°¡ ¾ø°í, ¹ßÄ¡ÇÏÁö ¾ÊÀ¸¸é ¾È µÈ´Ù.
  • acute pyelonephritis
    ¸¸¼º ½Å¿ì½Å¿°
    ¸¸¼ºÀÇ ¼¼´¢°ü °£ÁúÀÇ ¿°Áõ°ú ½Å Á¶Á÷ÀÇ ¹ÝÈç ¹× ½Å¹è¿Í ½Å¿ìÀÇ º´º¯À» µ¿¹ÝÇÏ´Â ÁúȯÀÌ´Ù. ¸¸¼º ½Å¿ì½Å¿°Àº ¸»±â ½Å ÁúȯÀÇ Áß¿äÇÑ ¿øÀÎÀ¸·Î ½Å ÀÌ½Ä È¯ÀÚ³ª Åõ¼® ȯÀÚÀÇ 11-20%¸¦ Â÷ÁöÇÑ´Ù. ¸¸¼º ½Å¿ì½Å¿°Àº ¸¸¼º Æó¼â¼º ½Å¿ì½Å¿°°ú ¿ª·ù¼º ½Åº´ÁõÀ¸·Î ³ª´«´Ù.
  • acute radiation sickness
    ±Þ¼º ¹æ»ç¼±Áõ
    ±Þ¼º ¹æ»ç¼± Àå¾Ö °¡¿îµ¥ Àü½Å Áõ»óÀ¸·Î¼­ ³ªÅ¸³ª´Â °ÍÀ» ¸»ÇÑ´Ù. Áï ÇÇ·Î, ½Ä¿å °¨Åð, ¿À½É, ±¸Åä µîÀÇ Áõ»óÀÌ ³ªÅ¸³­´Ù. ´ëºÎºÐ Àü½Å¿¡ ÇÇÆøÇÑ °æ¿ì¿¡ »ý±â´Âµ¥ ±¹¼Ò ÇÇÆøÀÌ¶óµµ ¾çÀÌ ¸¹À» ¶§¿¡´Â »ý±ä´Ù. ƯÈ÷ ¹æ»ç¼± Ä¡·áÀÇ °æ¿ì¿¡µµ ³ú³ª º¹ºÎ¿¡ Á¶»çÇÑ °æ¿ì¿¡ ÀÏÀ¸Å°±â ½±´Ù.
  • acute rejection vasculitis
    ±Þ¼º °ÅºÎ Ç÷°ü¿°
    ÀÌ½Ä ÈÄ ¸î °³¿ù ³»¿¡ ³ªÅ¸³ª°Å³ª ¸é¿ª¾ïÁ¦¿ä¹ýÀ» Áß´ÜÇßÀ» ¶§ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ È¯ÀÚ´Â ÀÌ½Ä Àå±âÀÇ ±â´ÉÀå¾Ö°¡ ÀÌ½Ä ¼ö¼ú ÈÄ °©Àڱ⠳ªÅ¸³ª¼­ Áö¼Ó¼ºÀ» º¸ÀÌ¸ç °í´ÜÀ§ÀÇ ¸é¿ª¾ïÁ¦¿ä¹ý¿¡ ÀÇÇØ¼­µµ Àß Ä¡À¯µÇÁö ¾Ê´Â´Ù.
  • acute respiratory distress syndrome
    ±Þ¼º È£Èí°ï¶õ ÁõÈıº
    ¼ºÀΠȣÈíºÎÀü, ¼ï Æó, ¹Ì¸¸¼º ÆóÆ÷ ¼Õ»ó, ±Þ¼º ÆóÆ÷ ¼Õ»ó, ¿Ü»ó¼º ÀæÀº Æó µîÀÌ ÀÖ´Ù. ¹Ì¸¸¼ºÀ¸·Î ÆóÆ÷ ¸ð¼¼Ç÷°üÀÌ ¼Õ»óÀ» ÀÔ¾î ÃÊ·¡µÇ¸ç ÀÓ»óÀûÀ¸·Î´Â ±Þ°ÝÈ÷ »ý±ä ½ÉÇÑ È£Èí°ï¶õ, ºó¸Æ, û»öÁõ ¹× »ê¼Ò¿ä¹ý¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â µ¿¸Æ Àú»ê¼ÒÁõ µîÀ» Ư¡À¸·Î ÇÑ´Ù.
  • acute rheumatic arthritis
    ±Þ¼º ·ù¸¶Æ¼½º¼º °üÀý¿°
  • acute rheumatic polyarthritis
    ±Þ¼º ·ù¸¶Æ¼½º¼º ´Ù¹ß °üÀý¿°, ±Þ¼º ·ù¸¶Æ¼½º¼º ´Ù¹ß¼º °üÀý¿°
  • acute rhinitis
    ±Þ¼º ºñ¿°
    ÄÚ¿¡ »ý±â´Â ±Þ¼º ¿°Áõ.
  • acute serum sickness
    ±Þ¼º Ç÷ûº´
    Àü½Å¼º ¸é¿ªº¹ÇÕü ÁúȯÀÇ ÀüÇüÀûÀÎ ¿¹ÀÌ´Ù. Çѵ¿¾È Çǵ¿¼º ¸é¿ªÀ» À§ÇØ »ç¿ëµÈ ´Ù·®ÀÇ ÀÌÁ¾ Ç÷ûÀÇ Åõ¿©¿¡ µû¸¥ ÈÄÀ¯ÁõÀÌ´Ù.
  • acute situational stress reaction
    ±Þ¼º »óȲ¼º ½ºÆ®·¹½º ¹ÝÀÀ
    ±ØµµÀÇ È¯°æÀû ½ºÆ®·¹½º¿¡ ´ëÇÑ ÀϽÃÀûÀÎ ¹ÝÀÀÀ¸·Î ±âÃÊÀûÀÎ Á¤½Å Àå¾Ö°¡ ¾ø´Â °³Àο¡°Ô ³ªÅ¸³­´Ù.
  • acute stage
    ±Þ¼º±â
    º´Àû °æ°ú¿¡ À־ ±Þ¼º »óÅ¿¡ ¸Ó¹«´Â ±â°£.
  • acute sublingual sialadenitis
    ±Þ¼º ¼³Çϼ±¿°
  • acute suppurative osteomyelitis
    ±Þ¼º È­³ó¼º °ñ¼ö¿°
    °ñ¼ö¿¡ »ý±â´Â °í¸§À» ¸¸µå´Â ±Þ¼º ¿°Áõ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
leukaemia, megakaryocytic, acute Nonlymphocytic leukaemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. Myelofibrosis or increased bone marrow reticulin is common.
(12 Dec 1998)
leukaemia, myelocytic, acute Progressive, malignant disease of the myeloid tissue in which the granular, polymorphonuclear leukocytes and their precursors predominate.
(12 Dec 1998)
leukaemia, nonlymphocytic, acute Acute leukaemia distinguished from acute lymphocytic leukaemia (all) by the morphology of the marrow and blood leukaemic cells. Cytoplasmic granules are usually present and the nucleus is usually large and irregular. Anll is more common in adults than all and occurs at any age.
(12 Dec 1998)
leukoencephalitis, acute haemorrhagic A rare, fatal postinfection or allergic demyelinating disease of the central nervous system having a fulminating course and occurring mainly in young adults. It is characterised by destruction of white matter to the point of liquefaction; widespread necrosis of blood vessel walls leading to the formation of multiple small haemorrhages in the involved areas and the exudation of fibrin into the surrounding tissue; and cellular infiltration of the necrotic areas.
(12 Dec 1998)
liver failure, acute A form of liver failure with rapid onset. It is often induced by the toxic effect of drugs and various toxic substances in experimental studies in animals and in clinical states in humans. If coma ensues, the constellation of neurological symptoms is referred to as hepatic encephalopathy.
(12 Dec 1998)
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
allogeneic antigen Genetic variations of the same antigens within a given species.
(05 Mar 2000)
antigen Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun.
See: early gene.
(18 Nov 1997)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
ÅëÇÕ°Ë»ö ¿Ï·á